microRNA information: hsa-miR-423-3p
Section | ID | link |
---|---|---|
Mature name: | hsa-miR-423-3p | miRbase |
Accession: | MIMAT0001340 | miRbase |
Precursor name: | hsa-mir-423 | miRbase |
Precursor accession: | MI0001445 | miRbase |
Symbol: | MIR423 | HGNC |
RefSeq ID: | NR_029945 | GenBank |
Sequence: | AGCUCGGUCUGAGGCCCCUCAGU |
Reported expression in cancers: hsa-miR-423-3p
miRNA | cancer | regulation | reporting | PUBMED | method |
---|---|---|---|---|---|
hsa-miR-423-3p | breast cancer | upregulation | "MicroRNA sequence and expression analysis in breas ......" | 21586611 | RNA-Seq |
hsa-miR-423-3p | colorectal cancer | upregulation | "MiR 423 3p enhances cell growth through inhibition ......" | 26402653 | qPCR |
hsa-miR-423-3p | endometrial cancer | deregulation | "In endometrial cancer cells expression levels of m ......" | 26535032 | |
hsa-miR-423-3p | esophageal cancer | upregulation | "In our study three miRNA-related SNPs: rs6505162 A ......" | 24205249 | |
hsa-miR-423-3p | head and neck cancer | deregulation | "A global miRNA profiling was done on 51 formalin-f ......" | 20145181 | Reverse transcription PCR |
hsa-miR-423-3p | liver cancer | upregulation | "MicroRNA 423 promotes cell growth and regulates G1 ......" | 21890460 |
Reported cancer pathway affected by hsa-miR-423-3p
miRNA | cancer | pathway | reporting | PUBMED | functional study |
---|---|---|---|---|---|
hsa-miR-423-3p | colorectal cancer | cell cycle pathway | "MiR 423 3p enhances cell growth through inhibition ......" | 26402653 | Cell proliferation assay; Cell Proliferation Assay; Transwell assay; Luciferase |
hsa-miR-423-3p | head and neck cancer | cell cycle pathway | "A global miRNA profiling was done on 51 formalin-f ......" | 20145181 | Flow cytometry |
hsa-miR-423-3p | liver cancer | cell cycle pathway | "MicroRNA 423 promotes cell growth and regulates G1 ......" | 21890460 |
Reported cancer prognosis affected by hsa-miR-423-3p
miRNA | cancer | prognosis | reporting | PUBMED | functional study |
---|---|---|---|---|---|
hsa-miR-423-3p | breast cancer | metastasis | "MicroRNA sequence and expression analysis in breas ......" | 21586611 | |
hsa-miR-423-3p | breast cancer | tumorigenesis | "Genetic analysis and preliminary function study of ......" | 25663458 | |
hsa-miR-423-3p | breast cancer | worse prognosis; drug resistance | "The aim of this study was to investigate the role ......" | 27746365 | |
hsa-miR-423-3p | colorectal cancer | metastasis; recurrence | "Also single nucleotide polymorphisms of genes enco ......" | 23173124 | |
hsa-miR-423-3p | colorectal cancer | tumorigenesis | "MiR 423 3p enhances cell growth through inhibition ......" | 26402653 | Cell proliferation assay; Cell Proliferation Assay; Transwell assay; Luciferase |
hsa-miR-423-3p | endometrial cancer | metastasis; tumorigenesis | "In endometrial cancer cells expression levels of m ......" | 26535032 | |
hsa-miR-423-3p | liver cancer | tumorigenesis; progression | "MicroRNA 423 promotes cell growth and regulates G1 ......" | 21890460 | |
hsa-miR-423-3p | liver cancer | worse prognosis | "Identification of miR 423 and miR 499 polymorphism ......" | 24854593 | |
hsa-miR-423-3p | lung squamous cell cancer | metastasis | "In this study five NSCLC cases with LN metastasis ......" | 26618049 |
Reported gene related to hsa-miR-423-3p
miRNA | cancer | gene | reporting | PUBMED |
---|
Expression profile in cancer corhorts:
Putative target regulations
miRNA | Gene | Cancer | Interaction | Correlation beta |
---|---|---|---|---|
hsa-miR-423-3p | ATP8B2 | 13 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; KIRP; LUSC; PRAD; SARC; THCA; STAD; UCEC | miRNAWalker2 validate | TCGA BLCA -0.588; TCGA BRCA -0.285; TCGA CESC -0.223; TCGA COAD -0.72; TCGA ESCA -0.521; TCGA HNSC -0.274; TCGA KIRP -0.17; TCGA LUSC -0.321; TCGA PRAD -0.186; TCGA SARC -0.261; TCGA THCA -0.26; TCGA STAD -0.612; TCGA UCEC -0.381 |
hsa-miR-423-3p | CDKN1A | 11 cancers: BLCA; BRCA; CESC; ESCA; LGG; LIHC; LUSC; PAAD; PRAD; THCA; STAD | miRNAWalker2 validate; miRTarBase | TCGA BLCA -0.2; TCGA BRCA -0.105; TCGA CESC -0.268; TCGA ESCA -0.325; TCGA LGG -0.248; TCGA LIHC -0.425; TCGA LUSC -0.4; TCGA PAAD -0.206; TCGA PRAD -0.227; TCGA THCA -0.177; TCGA STAD -0.123 |
hsa-miR-423-3p | DPYSL3 | 15 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; KIRP; LGG; LIHC; LUSC; PAAD; PRAD; SARC; STAD; UCEC | miRNAWalker2 validate | TCGA BLCA -0.889; TCGA BRCA -0.2; TCGA CESC -0.411; TCGA COAD -0.924; TCGA ESCA -0.8; TCGA HNSC -0.354; TCGA KIRP -1.08; TCGA LGG -0.213; TCGA LIHC -0.419; TCGA LUSC -0.313; TCGA PAAD -0.448; TCGA PRAD -0.489; TCGA SARC -0.557; TCGA STAD -0.867; TCGA UCEC -0.682 |
hsa-miR-423-3p | EEF1A1 | 11 cancers: BLCA; BRCA; ESCA; HNSC; KIRC; KIRP; LGG; LUAD; LUSC; PAAD; STAD | miRNAWalker2 validate | TCGA BLCA -0.156; TCGA BRCA -0.09; TCGA ESCA -0.177; TCGA HNSC -0.06; TCGA KIRC -0.121; TCGA KIRP -0.209; TCGA LGG -0.154; TCGA LUAD -0.186; TCGA LUSC -0.072; TCGA PAAD -0.176; TCGA STAD -0.124 |
hsa-miR-423-3p | EIF4B | 9 cancers: BLCA; BRCA; HNSC; KIRC; KIRP; LGG; LUAD; STAD; UCEC | miRNAWalker2 validate | TCGA BLCA -0.132; TCGA BRCA -0.081; TCGA HNSC -0.124; TCGA KIRC -0.135; TCGA KIRP -0.268; TCGA LGG -0.157; TCGA LUAD -0.138; TCGA STAD -0.073; TCGA UCEC -0.097 |
hsa-miR-423-3p | FOXJ2 | 11 cancers: BLCA; CESC; COAD; HNSC; KIRP; LIHC; LUAD; PRAD; SARC; STAD; UCEC | miRNAWalker2 validate | TCGA BLCA -0.184; TCGA CESC -0.103; TCGA COAD -0.07; TCGA HNSC -0.081; TCGA KIRP -0.234; TCGA LIHC -0.156; TCGA LUAD -0.088; TCGA PRAD -0.124; TCGA SARC -0.119; TCGA STAD -0.163; TCGA UCEC -0.265 |
hsa-miR-423-3p | FRMD4A | 11 cancers: BLCA; CESC; COAD; HNSC; KIRP; LUSC; PAAD; PRAD; THCA; STAD; UCEC | miRNAWalker2 validate | TCGA BLCA -0.138; TCGA CESC -0.158; TCGA COAD -0.234; TCGA HNSC -0.091; TCGA KIRP -0.499; TCGA LUSC -0.462; TCGA PAAD -0.217; TCGA PRAD -0.083; TCGA THCA -0.164; TCGA STAD -0.304; TCGA UCEC -0.134 |
hsa-miR-423-3p | KDSR | 10 cancers: BLCA; CESC; KIRP; LIHC; LUAD; PAAD; PRAD; SARC; THCA; UCEC | miRNAWalker2 validate | TCGA BLCA -0.11; TCGA CESC -0.106; TCGA KIRP -0.104; TCGA LIHC -0.165; TCGA LUAD -0.1; TCGA PAAD -0.141; TCGA PRAD -0.157; TCGA SARC -0.162; TCGA THCA -0.051; TCGA UCEC -0.176 |
hsa-miR-423-3p | NACC2 | 15 cancers: BLCA; BRCA; COAD; ESCA; HNSC; KIRC; KIRP; LGG; LUSC; PAAD; PRAD; SARC; THCA; STAD; UCEC | miRNAWalker2 validate | TCGA BLCA -0.383; TCGA BRCA -0.141; TCGA COAD -0.128; TCGA ESCA -0.332; TCGA HNSC -0.103; TCGA KIRC -0.238; TCGA KIRP -0.442; TCGA LGG -0.204; TCGA LUSC -0.156; TCGA PAAD -0.169; TCGA PRAD -0.333; TCGA SARC -0.439; TCGA THCA -0.283; TCGA STAD -0.427; TCGA UCEC -0.154 |
hsa-miR-423-3p | NTN1 | 12 cancers: BLCA; CESC; COAD; ESCA; HNSC; KIRC; KIRP; LIHC; PRAD; SARC; THCA; STAD | miRNAWalker2 validate | TCGA BLCA -0.815; TCGA CESC -0.349; TCGA COAD -0.701; TCGA ESCA -0.875; TCGA HNSC -0.267; TCGA KIRC -0.92; TCGA KIRP -1.384; TCGA LIHC -0.285; TCGA PRAD -0.651; TCGA SARC -0.465; TCGA THCA -0.641; TCGA STAD -1.095 |
hsa-miR-423-3p | REEP2 | 10 cancers: BLCA; COAD; ESCA; KIRC; KIRP; LGG; PRAD; SARC; STAD; UCEC | miRNAWalker2 validate | TCGA BLCA -0.605; TCGA COAD -0.688; TCGA ESCA -0.756; TCGA KIRC -0.679; TCGA KIRP -0.995; TCGA LGG -0.255; TCGA PRAD -0.372; TCGA SARC -0.529; TCGA STAD -1.128; TCGA UCEC -0.17 |
hsa-miR-423-3p | RNF185 | 9 cancers: BLCA; ESCA; HNSC; KIRP; LGG; PRAD; SARC; STAD; UCEC | miRNAWalker2 validate | TCGA BLCA -0.058; TCGA ESCA -0.092; TCGA HNSC -0.06; TCGA KIRP -0.121; TCGA LGG -0.11; TCGA PRAD -0.101; TCGA SARC -0.23; TCGA STAD -0.118; TCGA UCEC -0.094 |
hsa-miR-423-3p | ROBO1 | 11 cancers: BLCA; COAD; HNSC; KIRC; KIRP; LGG; LUAD; PAAD; PRAD; THCA; STAD | miRNAWalker2 validate | TCGA BLCA -0.306; TCGA COAD -0.287; TCGA HNSC -0.16; TCGA KIRC -0.209; TCGA KIRP -0.767; TCGA LGG -0.441; TCGA LUAD -0.135; TCGA PAAD -0.476; TCGA PRAD -0.521; TCGA THCA -0.328; TCGA STAD -0.383 |
hsa-miR-423-3p | SMARCA2 | 15 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; KIRC; KIRP; LGG; LIHC; LUAD; PRAD; SARC; STAD; UCEC | miRNAWalker2 validate | TCGA BLCA -0.182; TCGA BRCA -0.076; TCGA CESC -0.144; TCGA COAD -0.1; TCGA ESCA -0.26; TCGA HNSC -0.255; TCGA KIRC -0.289; TCGA KIRP -0.46; TCGA LGG -0.18; TCGA LIHC -0.49; TCGA LUAD -0.152; TCGA PRAD -0.142; TCGA SARC -0.176; TCGA STAD -0.267; TCGA UCEC -0.291 |
hsa-miR-423-3p | SPTBN1 | 10 cancers: BLCA; HNSC; KIRC; KIRP; LIHC; LUSC; PAAD; PRAD; THCA; UCEC | miRNAWalker2 validate | TCGA BLCA -0.149; TCGA HNSC -0.253; TCGA KIRC -0.168; TCGA KIRP -0.344; TCGA LIHC -0.203; TCGA LUSC -0.37; TCGA PAAD -0.267; TCGA PRAD -0.236; TCGA THCA -0.134; TCGA UCEC -0.155 |
hsa-miR-423-3p | WNK1 | 10 cancers: BLCA; CESC; HNSC; KIRC; KIRP; LUAD; PRAD; THCA; STAD; UCEC | miRNAWalker2 validate | TCGA BLCA -0.135; TCGA CESC -0.229; TCGA HNSC -0.202; TCGA KIRC -0.347; TCGA KIRP -0.743; TCGA LUAD -0.112; TCGA PRAD -0.103; TCGA THCA -0.124; TCGA STAD -0.081; TCGA UCEC -0.097 |
hsa-miR-423-3p | YIPF5 | 9 cancers: BLCA; COAD; ESCA; HNSC; KIRP; LUAD; LUSC; PRAD; THCA | miRNAWalker2 validate | TCGA BLCA -0.07; TCGA COAD -0.103; TCGA ESCA -0.124; TCGA HNSC -0.101; TCGA KIRP -0.181; TCGA LUAD -0.117; TCGA LUSC -0.165; TCGA PRAD -0.075; TCGA THCA -0.062 |
hsa-miR-423-3p | EMCN | 16 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; KIRC; KIRP; LIHC; LUAD; LUSC; PAAD; PRAD; SARC; STAD; UCEC | MirTarget | TCGA BLCA -0.468; TCGA BRCA -0.493; TCGA CESC -0.735; TCGA COAD -0.731; TCGA ESCA -0.575; TCGA HNSC -0.569; TCGA KIRC -0.643; TCGA KIRP -1.354; TCGA LIHC -0.751; TCGA LUAD -0.299; TCGA LUSC -1.106; TCGA PAAD -0.431; TCGA PRAD -0.296; TCGA SARC -0.23; TCGA STAD -0.521; TCGA UCEC -0.968 |
hsa-miR-423-3p | CBX7 | 16 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; KIRC; KIRP; LGG; LIHC; LUAD; LUSC; PRAD; SARC; STAD; UCEC | MirTarget | TCGA BLCA -0.465; TCGA BRCA -0.49; TCGA CESC -0.301; TCGA COAD -0.266; TCGA ESCA -0.53; TCGA HNSC -0.316; TCGA KIRC -0.27; TCGA KIRP -0.601; TCGA LGG -0.191; TCGA LIHC -0.281; TCGA LUAD -0.101; TCGA LUSC -0.33; TCGA PRAD -0.306; TCGA SARC -0.852; TCGA STAD -0.736; TCGA UCEC -0.744 |
hsa-miR-423-3p | FRY | 17 cancers: BLCA; BRCA; COAD; ESCA; HNSC; KIRC; KIRP; LGG; LIHC; LUAD; LUSC; PAAD; PRAD; SARC; THCA; STAD; UCEC | MirTarget; PITA | TCGA BLCA -0.256; TCGA BRCA -0.194; TCGA COAD -0.482; TCGA ESCA -0.74; TCGA HNSC -0.598; TCGA KIRC -0.624; TCGA KIRP -0.965; TCGA LGG -0.31; TCGA LIHC -0.265; TCGA LUAD -0.143; TCGA LUSC -0.629; TCGA PAAD -0.267; TCGA PRAD -0.374; TCGA SARC -0.844; TCGA THCA -0.128; TCGA STAD -0.469; TCGA UCEC -0.571 |
hsa-miR-423-3p | ZBTB46 | 10 cancers: BLCA; BRCA; COAD; ESCA; HNSC; KIRC; KIRP; LUSC; STAD; UCEC | MirTarget | TCGA BLCA -0.191; TCGA BRCA -0.113; TCGA COAD -0.425; TCGA ESCA -0.355; TCGA HNSC -0.278; TCGA KIRC -0.207; TCGA KIRP -0.271; TCGA LUSC -0.655; TCGA STAD -0.086; TCGA UCEC -0.503 |
hsa-miR-423-3p | AKAP2 | 14 cancers: BLCA; BRCA; COAD; ESCA; HNSC; KIRC; KIRP; LUAD; LUSC; PAAD; PRAD; SARC; THCA; UCEC | PITA | TCGA BLCA -0.887; TCGA BRCA -0.186; TCGA COAD -0.393; TCGA ESCA -0.536; TCGA HNSC -0.885; TCGA KIRC -0.248; TCGA KIRP -0.942; TCGA LUAD -0.175; TCGA LUSC -1.22; TCGA PAAD -0.359; TCGA PRAD -0.706; TCGA SARC -0.592; TCGA THCA -0.585; TCGA UCEC -0.857 |
hsa-miR-423-3p | DLL1 | 10 cancers: BLCA; BRCA; HNSC; KIRC; KIRP; LGG; LIHC; PRAD; STAD; UCEC | PITA | TCGA BLCA -0.216; TCGA BRCA -0.498; TCGA HNSC -0.165; TCGA KIRC -0.252; TCGA KIRP -1.189; TCGA LGG -0.56; TCGA LIHC -0.608; TCGA PRAD -0.145; TCGA STAD -0.156; TCGA UCEC -0.429 |
hsa-miR-423-3p | ZNF561 | 11 cancers: CESC; COAD; ESCA; HNSC; KIRC; KIRP; LIHC; LUAD; PRAD; SARC; STAD | miRNAWalker2 validate | TCGA CESC -0.143; TCGA COAD -0.068; TCGA ESCA -0.164; TCGA HNSC -0.13; TCGA KIRC -0.126; TCGA KIRP -0.14; TCGA LIHC -0.155; TCGA LUAD -0.114; TCGA PRAD -0.12; TCGA SARC -0.193; TCGA STAD -0.098 |
hsa-miR-423-3p | RAB14 | 10 cancers: CESC; COAD; KIRC; KIRP; LGG; LIHC; LUAD; LUSC; OV; UCEC | MirTarget; PITA | TCGA CESC -0.095; TCGA COAD -0.061; TCGA KIRC -0.153; TCGA KIRP -0.166; TCGA LGG -0.126; TCGA LIHC -0.137; TCGA LUAD -0.115; TCGA LUSC -0.063; TCGA OV -0.115; TCGA UCEC -0.067 |
hsa-miR-423-3p | CYFIP2 | 10 cancers: ESCA; HNSC; KIRC; KIRP; LGG; LUAD; LUSC; SARC; STAD; UCEC | miRNAWalker2 validate | TCGA ESCA -0.45; TCGA HNSC -0.354; TCGA KIRC -0.544; TCGA KIRP -0.363; TCGA LGG -0.228; TCGA LUAD -0.159; TCGA LUSC -0.605; TCGA SARC -0.758; TCGA STAD -0.363; TCGA UCEC -0.185 |
Enriched cancer pathways of putative targets